Related Experiment Video
Updated: Jan 20, 2026
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives
Ilaria Cavallari1, Loredana Urso2, Evgeniya Sharova1
1Immunologia e Diagnostica Molecolare Oncologica (IDMO), Istituto Oncologico Veneto IOV- IRCCS, Padova, Italy.
Abstract:
Malignant pleural mesothelioma (MPM) is an aggressive tumor linked to asbestos exposure. Although the risk factors for MPM are well-known, the majority of MPM patients are diagnosed at an advanced stage and have a very poor prognosis. Circulating biomarkers for early diagnosis remain to be identified, and the current standard for MPM diagnosis relies on pleural biopsies. Robust non-invasive tests for the screening of asbestos-exposed subjects are therefore an important unmet clinical need. This review provides a critical summary of recent liquid biopsy-based studies aimed at discovering novel blood-based circulating biomarkers for the early diagnosis and prognostic stratification of MPM patients.
Insights
Identifying blood-based biomarkers is crucial for early diagnosis of malignant pleural mesothelioma (MPM), an aggressive cancer linked to asbestos. This review summarizes liquid biopsy studies seeking non-invasive tests for MPM screening and prognosis.
Area of Science:
- Oncology
- Biomarker Discovery
- Environmental Health
Background:
- Malignant pleural mesothelioma (MPM) is an aggressive asbestos-related cancer with poor prognosis.
- Current diagnosis relies on invasive pleural biopsies, highlighting a need for non-invasive methods.
- Early detection and prognostic stratification are critical unmet needs for MPM patients.
Purpose of the Study:
- To critically review recent liquid biopsy studies for novel blood-based biomarkers in MPM.
- To assess the potential of circulating biomarkers for early diagnosis of MPM.
- To evaluate biomarkers for prognostic stratification in MPM patients.
Main Methods:
- Systematic review of recent literature on liquid biopsy in MPM.
- Analysis of studies focusing on blood-derived circulating biomarkers.
- Evaluation of diagnostic and prognostic performance of identified biomarkers.
Main Results:
- Several circulating biomarkers show promise for MPM detection and prognosis.
- Liquid biopsy approaches are advancing the search for non-invasive MPM diagnostics.
- Further validation is needed to establish clinical utility of blood biomarkers.
Conclusions:
- Blood-based biomarkers hold significant potential for non-invasive MPM diagnosis and prognosis.
- Liquid biopsy research is crucial for addressing the unmet clinical need in MPM.
- Future studies should focus on validating these biomarkers for clinical application.
More Related Videos
Related Concept Videos
08:01Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
05:26A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications
07:54Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
03:22Local Anesthetic Thoracoscopy for Undiagnosed Pleural Effusion
06:24Examining Changes in HRV and Emotion Following Artmaking with Three Different Art Materials
14:54Biobanking of Human Aqueous and Vitreous Liquid Biopsies for Molecular Analyses